Yaqin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yaqin Wang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Beibei Zhao
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications - Ben-Quan Qi
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications - Fang Liu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications - Ju Gao
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China
10 shared publications - Li Zhang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin China
10 shared publications - Li-Xian Chang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S2. Overall Survival and Event-free Survival Outcome (A) Overall survival (OS) according to risk group. (B) Event-free survival (EFS) according to risk group. (C) OS stratified by following HSCT status. (D) EFS stratified by following HSCT status.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S2. Overall Survival and Event-free Survival Outcome (A) Overall survival (OS) according to risk group. (B) Event-free survival (EFS) according to risk group. (C) OS stratified by following HSCT status. (D) EFS stratified by following HSCT status.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S1. Study Representativeness Table
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S1. Study Representativeness Table
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S2. Response outcomes of induction therapy
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S2. Response outcomes of induction therapy
- Open Access
- 2 September 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (9) , e70802
PRMT7‐mediated arginine methylation of FOXK activates Wnt/β‐catenin signalling to drive doxorubicin resistance in diffuse large B‐cell lymphoma
Background: Doxorubicin, an anthracycline chemotherapeutic agent, is widely used in diffuse large B‑cell lymphoma (DLBCL) treatment, yet its clinical efficacy is often compromised by drug resistance. Protein arginine methyltransferase 7 (PRMT7) is a methyltransferase implicated in tumourigenesis and cancer progression. However, its precise role and underlying mechanisms in DLBCL progression and doxorubicin resistance remain unclear. Methods: We analysed PRMT7 expression in DLBCL cell lines and patient specimens using bioinformatic databases, western blotting, reverse Transcription Polymerase Chain Reactionand immunohistochemistry. Functional studies were performed in DLBCL cell lines through CRISPR/Cas9‑mediated knockout and overexpression systems, combined with in vitro assays for proliferation, apoptosis and doxorubicin sensitivity, as well as in vivo xenograft models. Mechanistically, co‑immunoprecipitation, arginine methylation assays and immunofluorescence were employed to characterise the PRMT7–Forkhead box K (FOXK)1/2–Dishevelled Segment Polarity Protein 2 (DVL2) axis and its modulation of Wnt/ (beta) β‑catenin signalling. In addition, we designed and evaluated FOXK‑methylation‑competitive inhibitory peptides for their capacity to sensitise DLBCL cells to doxorubicin. Results: Our study revealed that PRMT7 is upregulated in DLBCL and promotes both tumour proliferation and doxorubicin resistance. Conversely, knockdown of PRMT7 inhibited DLBCL cell proliferation and enhanced sensitivity to doxorubicin. Mechanistically, PRMT7 catalyses arginine methylation of FOXK1 at arginine (R) 191 and FOXK2 at R144, which markedly increases their binding affinity for DVL2 and facilitates DVL2 nuclear translocation. This event leads to constitutive activation of the Wnt/β‑catenin signalling pathway. Importantly, we developed a FOXK‑derived peptide that competitively inhibits FOXK methylation, suppresses Wnt/β‑catenin signalling and significantly potentiates the antitumour efficacy of doxorubicin in DLBCL. Conclusion: Our findings indicate that the PRMT7/FOXK/DVL2/Wnt‐β‐catenin axis serves as a novel driver of DLBCL progression and doxorubicin resistance. Targeting the PRMT7–FOXK methylation interface may offer a potential therapeutic approach for overcoming doxorubicin resistance in DLBCL, although further validation in clinical settings is warranted. Key points: Upregulated PRMT7 drives DLBCL progression and doxorubicin resistance PRMT7 methylates FOXK1 at arginine 191 and FOXK2 at arginine 144 FOXK1/2 methylation enhances interaction with DVL2 and promotes nuclear translocation FOXK1/2 methylation dactivate Wnt/ß-catenin signaling through DVL2 nuclear entry A novel peptide inhibitory blocks FOXK1/2 methylation and restores doxorubicin sensitivity
- 2 September 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (9) , e70802
Open AccessPRMT7‐mediated arginine methylation of FOXK activates Wnt/β‐catenin signalling to drive doxorubicin resistance in diffuse large B‐cell lymphoma
Background: Doxorubicin, an anthracycline chemotherapeutic agent, is widely used in diffuse large B‑cell lymphoma (DLBCL) treatment, yet its clinical efficacy is often compromised by drug resistance. Protein arginine methyltransferase 7 (PRMT7) is a methyltransferase implicated in tumourigenesis and cancer progression. However, its precise role and underlying mechanisms in DLBCL progression and doxorubicin resistance remain unclear. Methods: We analysed PRMT7 expression in DLBCL cell lines and patient specimens using bioinformatic databases, western blotting, reverse Transcription Polymerase Chain Reactionand immunohistochemistry. Functional studies were performed in DLBCL cell lines through CRISPR/Cas9‑mediated knockout and overexpression systems, combined with in vitro assays for proliferation, apoptosis and doxorubicin sensitivity, as well as in vivo xenograft models. Mechanistically, co‑immunoprecipitation, arginine methylation assays and immunofluorescence were employed to characterise the PRMT7–Forkhead box K (FOXK)1/2–Dishevelled Segment Polarity Protein 2 (DVL2) axis and its modulation of Wnt/ (beta) β‑catenin signalling. In addition, we designed and evaluated FOXK‑methylation‑competitive inhibitory peptides for their capacity to sensitise DLBCL cells to doxorubicin. Results: Our study revealed that PRMT7 is upregulated in DLBCL and promotes both tumour proliferation and doxorubicin resistance. Conversely, knockdown of PRMT7 inhibited DLBCL cell proliferation and enhanced sensitivity to doxorubicin. Mechanistically, PRMT7 catalyses arginine methylation of FOXK1 at arginine (R) 191 and FOXK2 at R144, which markedly increases their binding affinity for DVL2 and facilitates DVL2 nuclear translocation. This event leads to constitutive activation of the Wnt/β‑catenin signalling pathway. Importantly, we developed a FOXK‑derived peptide that competitively inhibits FOXK methylation, suppresses Wnt/β‑catenin signalling and significantly potentiates the antitumour efficacy of doxorubicin in DLBCL. Conclusion: Our findings indicate that the PRMT7/FOXK/DVL2/Wnt‐β‐catenin axis serves as a novel driver of DLBCL progression and doxorubicin resistance. Targeting the PRMT7–FOXK methylation interface may offer a potential therapeutic approach for overcoming doxorubicin resistance in DLBCL, although further validation in clinical settings is warranted. Key points: Upregulated PRMT7 drives DLBCL progression and doxorubicin resistance PRMT7 methylates FOXK1 at arginine 191 and FOXK2 at arginine 144 FOXK1/2 methylation enhances interaction with DVL2 and promotes nuclear translocation FOXK1/2 methylation dactivate Wnt/ß-catenin signaling through DVL2 nuclear entry A novel peptide inhibitory blocks FOXK1/2 methylation and restores doxorubicin sensitivity
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S2. Overall Survival and Event-free Survival Outcome (A) Overall survival (OS) according to risk group. (B) Event-free survival (EFS) according to risk group. (C) OS stratified by following HSCT status. (D) EFS stratified by following HSCT status.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S2. Overall Survival and Event-free Survival Outcome (A) Overall survival (OS) according to risk group. (B) Event-free survival (EFS) according to risk group. (C) OS stratified by following HSCT status. (D) EFS stratified by following HSCT status.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Purpose:Venetoclax (VEN) has shown excellent activity in eliminating acute myeloid leukemia (AML) blasts in preclinical and clinical trials, but clinical data in pediatric newly diagnosed AML (ND-AML) remain limited. We evaluated VEN plus modified-intensity idarubicin and cytarabine chemotherapy (VIA) in childhood ND-AML.Patients and Methods:In an open-label, single-arm, multicenter prospective clinical trial, 65 pediatric patients with ND-AML received VIA induction. Consolidation was guided on response to induction and individualized risk stratification. Primary end point was complete remission and measurable residual disease (MRD) response rates.Results:After induction cycle 1, complete remission and MRD negativity was 90.8% and 78.5%, increasing to 96.8% and 87.3% following induction cycle 2. A total of 28 (43.2%) patients underwent hematopoietic stem cell transplantation without engraftment failure. Patients with core-binding factor (CBF) AML [t(8;21) and inv(16)/t(16;16)] achieved a favorable response rate, but the median log10 reduction of transcript levels was suboptimal [-1.7 (cycle 1) and -2.6 (cycle 2) for RUNX1::RUNX1T1 and -2.3 and -2.5 for CBFB::MYH11]. Disease relapse was frequently observed in KIT mutation, RUNX1::RUNX1T1, and CBFB::MYH11. The most common grade 3 to 4 toxicities were hematologic toxicities and febrile neutropenia. No treatment-related deaths occurred. With a median follow-up of 15.7 months, the estimated 12-month overall survival and event-free survival was 92.3% (95% confidence interval, 86.0–99.8) and 79.1% (95% confidence interval, 69.6–90.0). MRD negativity after cycle 1 correlated with superior long-term survival (P < 0.001).Conclusions:The VIA regimen is highly effective and relatively safe in children with ND-AML, with deep remission and favorable survival outcomes observed.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Purpose:Venetoclax (VEN) has shown excellent activity in eliminating acute myeloid leukemia (AML) blasts in preclinical and clinical trials, but clinical data in pediatric newly diagnosed AML (ND-AML) remain limited. We evaluated VEN plus modified-intensity idarubicin and cytarabine chemotherapy (VIA) in childhood ND-AML.Patients and Methods:In an open-label, single-arm, multicenter prospective clinical trial, 65 pediatric patients with ND-AML received VIA induction. Consolidation was guided on response to induction and individualized risk stratification. Primary end point was complete remission and measurable residual disease (MRD) response rates.Results:After induction cycle 1, complete remission and MRD negativity was 90.8% and 78.5%, increasing to 96.8% and 87.3% following induction cycle 2. A total of 28 (43.2%) patients underwent hematopoietic stem cell transplantation without engraftment failure. Patients with core-binding factor (CBF) AML [t(8;21) and inv(16)/t(16;16)] achieved a favorable response rate, but the median log10 reduction of transcript levels was suboptimal [-1.7 (cycle 1) and -2.6 (cycle 2) for RUNX1::RUNX1T1 and -2.3 and -2.5 for CBFB::MYH11]. Disease relapse was frequently observed in KIT mutation, RUNX1::RUNX1T1, and CBFB::MYH11. The most common grade 3 to 4 toxicities were hematologic toxicities and febrile neutropenia. No treatment-related deaths occurred. With a median follow-up of 15.7 months, the estimated 12-month overall survival and event-free survival was 92.3% (95% confidence interval, 86.0–99.8) and 79.1% (95% confidence interval, 69.6–90.0). MRD negativity after cycle 1 correlated with superior long-term survival (P < 0.001).Conclusions:The VIA regimen is highly effective and relatively safe in children with ND-AML, with deep remission and favorable survival outcomes observed.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S1. Study Representativeness Table
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S1. Study Representativeness Table
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S2. Response outcomes of induction therapy
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S2. Response outcomes of induction therapy